University Hospital of Wales, Cardiff, UK.
Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Cochrane Database Syst Rev. 2021 Aug 6;8(8):CD013664. doi: 10.1002/14651858.CD013664.pub2.
Trabeculectomy is a surgical treatment for glaucoma to lower intraocular pressure with high success rates; however, it is often associated with an increased rate of cataract formation. Cataract can cause symptoms such as glare in bright conditions, foggy vision, and difficulty in driving at night. Cataract extraction surgery is highly successful in improving vision, but it comes at a cost of trabeculectomy failure, with a reported risk of 30% to 40%. An additional intervention to promote trabeculectomy survival after cataract extraction is needed. This review encompassed all adjunctive therapies used at the time of cataract surgery to increase trabeculectomy survival rate.
To investigate the effect of the adjunctive modulation of wound healing during cataract surgery on the survival of a previously functioning trabeculectomy.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; which contains the Cochrane Eyes and Vision Trials Register; 2021, Issue 4); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; ClinicalTrials.gov; and the WHO ICTRP. We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 14 April 2021.
We planned to include all randomised controlled trials (RCTs) of participants who had a functioning trabeculectomy and were undergoing cataract surgery that compared any adjunctive therapy intended to modulate wound healing (such as 5-fluorouracil, mitomycin C, or anti-vascular endothelial growth factor (VEGF) therapy) with no adjuvant therapy. DATA COLLECTION AND ANALYSIS: We used standard methods expected by Cochrane. Our primary outcome was trabeculectomy failure at 6 months and 12 months after cataract surgery. Secondary outcomes were mean intraocular pressure difference from pre-cataract surgery baseline to 6 to 18 months post-cataract surgery; number of medications required to control eye pressure compared to before cataract surgery; bleb appearance as measured by a summation score of the Moorfields bleb grading system or other equivalent numerical grading systems; visual field progression measured by difference in mean deviation from baseline; and any complications.
We did not identify any RCTs of adjunctive modulation of wound healing during cataract surgery to promote survival of a previous trabeculectomy.
AUTHORS' CONCLUSIONS: There is a need for an RCT to investigate the role of adjuvant wound modulating therapy at the time of cataract surgery to promote survival of a functioning trabeculectomy.
小梁切除术是一种治疗青光眼的手术,通过降低眼内压来取得较高的成功率;然而,它通常与白内障形成率的增加有关。白内障可导致畏光、视力模糊和夜间驾驶困难等症状。白内障摘除术在改善视力方面非常成功,但它会导致小梁切除术失败,据报道风险为 30%至 40%。需要一种额外的干预措施来促进白内障摘除术后小梁切除术的存活。本综述包括在白内障手术时使用的所有辅助治疗方法,以提高小梁切除术的存活率。
研究白内障手术时辅助调节伤口愈合对先前功能正常的小梁切除术存活的影响。
我们检索了 Cochrane 中央对照试验注册库(CENTRAL,包含 Cochrane 眼科和视觉试验登记册;2021 年,第 4 期);Ovid MEDLINE;Ovid Embase;ISRCTN 登记处;ClinicalTrials.gov;以及世界卫生组织 ICTRP。我们在试验的电子检索中没有使用任何日期或语言限制。我们最后一次在 2021 年 4 月 14 日检索了电子数据库。
我们计划纳入所有参与者的随机对照试验(RCTs),这些参与者先前有功能正常的小梁切除术,并正在接受白内障手术,比较任何旨在调节伤口愈合的辅助治疗(如 5-氟尿嘧啶、丝裂霉素 C 或抗血管内皮生长因子(VEGF)治疗)与无辅助治疗。
我们使用了 Cochrane 预期的标准方法。我们的主要结局是白内障手术后 6 个月和 12 个月时小梁切除术的失败。次要结局是白内障术前基线至白内障术后 6 至 18 个月期间的平均眼内压差异;与白内障术前相比,控制眼压所需的药物数量;通过 Moorfields 滤过泡分级系统或其他等效数值分级系统的总和评分测量的滤过泡外观;通过从基线的平均偏差差异测量的视野进展;以及任何并发症。
我们没有发现任何关于白内障手术时辅助调节伤口愈合以促进先前小梁切除术存活的 RCTs。
需要一项 RCT 来研究白内障手术时辅助伤口调节治疗在促进功能正常的小梁切除术存活中的作用。